Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Portuguese researchers lead international consortium to develop novel clinical drug

30.10.2008
IMM leads first Portuguese coordination of FP-7 Marie-Curie Action IAPP (Industry-Academia Partnerships and Pathways) in partnership with the biotech company BIOALVO.

A five-partner European consortium coordinated by Portuguese researchers from the Instituto de Medicina Molecular (IMM) in Lisbon will perform the industrial development of a novel pharmaceutical drug. This novel drug has analgesic properties and has potential therapeutic application in the fight against neurodegenerative diseases such as Alzheimer’s or Parkinson’s diseases.

The compound (BLV200704) was conceived by Miguel Castanho’s research team, who is an IMM researcher, and was then licensed to the biotech company BIOALVO, which collaborated in subsequent stages of development of the drug.

The first steps of the research that lead to the development of BLV200704 resulted from collaboration between Miguel Castanho’s and Isaura Tavares’ research teams (IMM and Faculdade de Medicina/IBMC, Oporto University, Portugal, respectively) and counted on BIOALVO partnership in a latter stage of development.

The industrial development of the drug by a consortium of the Portuguese teams – IMM and BIOALVO - and two other from Spain and Germany is now approved by Marie-Curie IAPP Action (Industry-Academia Partnerships and Pathways – IAPP **), will involve approximately 600.000,00 Euros and is coordinated by Miguel Castanho at IMM, Lisbon.

The project, called PEP2BRAIN, will consolidate the pharmacological development of BLV200704 and its potential derivatives.

This is the first Portuguese partnership successfully approved by the demanding and highly competitive IAPP Marie-Curie Action from the European Seventh Framework Programme (FP-7). Marie-Curie Actions from the FP-7 “People” Programme, and in particular IAPP, seek the support of innovative partnerships between public research centers and private institutions, namely small and medium enterprises, which have the ultimate goal of developing novel products and solutions.

“The EU approval of this project shows the emergence of an economy of innovation in Portugal and reflects the growth of scientific knowledge and a novel attitude of Portuguese researchers”, says Miguel Castanho, researcher at IMM and coordinator of the present consortium. “In our specific case, the partnership with industry, namely with BIOALVO, has been highly productive and reveals the potential to develop novel products capable of contributing to the enhancement of the life standards, especially of those who suffer from disease. This potential has been recognized by the panel of experts that recommended the approval of our application to EU’s IAPP Action.”

Patrícia Calado, BIOALVO’s Drug Discovery and Development Director, said: “It is very rewarding for BIOALVO to be the first Portuguese company to successfully accomplish the evaluation step of an FP7 IAPP proposal. The achievement of this milestone reinforces the value of establishing high quality partnerships between industry and academia. The work developed in collaboration with the group of Prof. Miguel Castanho is a combined effort acknowledged by the European Commission as a high-quality translational research program which is now successfully moving into advanced phases of drug development”.

* Members of the consortium: Instituto de Medicina Molecular (Portugal), BIOALVO SA (Portugal), University of Girona (Spain), Synovo GmbH (Germany) and University Eberhard Karls, Tübingen (Germany).

Marta Agostinho | alfa
Further information:
http://cordis.europa.eu/fp7/people/industry-academia_en.html
http://www.imm.ul.pt

Further reports about: Alzheimer BIOALVO CONSORTIUM Development Drug FP-7 IAPP IMM Lead Marie-Curie Molecular Parkinson develop neurodegenerative disease novel

More articles from Life Sciences:

nachricht The interactome of infected neural cells reveals new therapeutic targets for Zika
23.01.2017 | D'Or Institute for Research and Education

nachricht Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery
20.01.2017 | GSI Helmholtzzentrum für Schwerionenforschung GmbH

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Quantum optical sensor for the first time tested in space – with a laser system from Berlin

For the first time ever, a cloud of ultra-cold atoms has been successfully created in space on board of a sounding rocket. The MAIUS mission demonstrates that quantum optical sensors can be operated even in harsh environments like space – a prerequi-site for finding answers to the most challenging questions of fundamental physics and an important innovation driver for everyday applications.

According to Albert Einstein's Equivalence Principle, all bodies are accelerated at the same rate by the Earth's gravity, regardless of their properties. This...

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

New technology for mass-production of complex molded composite components

23.01.2017 | Process Engineering

Quantum optical sensor for the first time tested in space – with a laser system from Berlin

23.01.2017 | Physics and Astronomy

The interactome of infected neural cells reveals new therapeutic targets for Zika

23.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>